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An imbalance between specialized pro-resolving
lipid mediators and pro-inflammatory leukotrienes
promotes instability of atherosclerotic plaques
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Chronic unresolved inflammation plays a causal role in the development of advanced
atherosclerosis, but the mechanisms that prevent resolution in atherosclerosis remain
unclear. Here, we use targeted mass spectrometry to identify specialized pro-resolving lipid
mediators (SPM) in histologically-defined stable and vulnerable regions of human carotid
atherosclerotic plaques. The levels of SPMs, particularly resolvin D1 (RvD1), and the ratio of
SPMs to pro-inflammatory leukotriene B4 (LTB4), are significantly decreased in the vulnerable
regions. SPMs are also decreased in advanced plaques of fat-fed Ldlr/ mice. Adminis-
tration of RvD1 to these mice during plaque progression restores the RvD1:LTB4 ratio to that of
less advanced lesions and promotes plaque stability, including decreased lesional oxidative
stress and necrosis, improved lesional efferocytosis, and thicker fibrous caps. These findings
provide molecular support for the concept that defective inflammation resolution contributes
to the formation of clinically dangerous plaques and offer a mechanistic rationale for SPM
therapy to promote plaque stability.
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C
hronic unresolved inflammation contributes to the devel-
opment of advanced atherosclerosis1–4. However, the
mechanisms that prevent resolution of inflammation in
atherosclerosis are poorly understood. Specialized pro-resolving
mediators (SPMs) represent a key family of resolution effectors
that include arachidonic acid (AA)-derived lipoxins like LXA4
and docosahexaenoic acid (DHA)-derived resolvins like RvD1
(ref. 5). SPMs are autacoids, which by definition suggests that
local tissue microenvironments play important roles in the
production and function of these mediators5. In this regard, the
balance of pro-inflammatory mediators and SPMs during acute
inflammation regulates the duration of the inflammatory
response and the timing of tissue resolution, for example, by
promoting apoptosis and efferocytic clearance of inflammatory
cells and other processes that dampen inflammation and repair
collateral damage6,7. An imbalance between these two classes of
mediators has been linked to a number of diverse chronic
inflammatory diseases8–10.
In the case of atherosclerosis, major gaps remain in our
understanding of the mechanisms and relevance of defective
resolution. In humans, the subset of atherosclerotic plaques that
are most important are those that at risk for precipitating acute
atherothrombotic clinical events, including myocardial infarction,
unstable angina, sudden cardiac death and stroke11. These so-
called ‘vulnerable’ plaques have distinct features, including
heightened inflammation and oxidative stress (OS); prominent
areas of necrosis, which are composed of dead cells not efficiently
cleared by efferocytosis; and thinning of a protective layer of
collagen (‘fibrous cap’) that overlies the areas of necrosis in more
stable lesions2,11,12. These features are suggestive of defective
resolution, but the mechanisms of this defect in advanced
atherosclerosis, including whether a deficiency of SPMs is
involved, are not known.
A possible clue to mechanism comes from a previous
study showing that macrophages in advanced atherosclerotic
plaques have abundant nuclear 5-lipoxygenase (5-LOX)13.
The potential significance of this observation is that nuclear
5-LOX, because of its proximity to LTA4 hydrolase, leads
to the conversion of AA to pro-inflammatory/pro-atherogenic
leukotrienes in macrophages14,15. In contrast, non-nuclear
5-LOX, potentially because of its proximity to 12/15-LOX,
promotes the conversion of AA to pro-resolving LXA4 or DHA
to RvD1 (ref. 16). Moreover, nuclear 5-LOX and the resultant
decrease in SPMs might trigger a ‘negative SPM feedback’ cycle,
because we recently showed that RvD1 promotes nuclear
exclusion of 5-LOX, which suppresses LTB4 and enhances
LXA4 in macrophages16. Thus, a decrease in SPMs may beget a
further decrease in SPM production by macrophages. However,
the critical issue as to whether SPMs and the SPM:leukotriene
balance are perturbed in advanced plaques is not known.
Here, we report that there is a significant imbalance between
5-LOX-derived SPMs, particularly RvD1, and leukotrienes, in
human vulnerable plaques compared with stable lesions. Similar
results were found in advanced murine atherosclerotic plaques,
and in this model we show that restoration of lesional RvD1
suppresses plaque progression. These findings provide critical
molecular support for the hypothesis that defective resolution
contributes to plaque progression and for the concept that SPM
‘restoration’ therapy could promote plaque stabilization.
Results
SPM and leukotriene imbalance in human vulnerable plaques.
Flash-frozen human plaques obtained from carotid endarter-
ectomy were dissected into ‘vulnerable’ and ‘stable’ regions based
on gross appearance (Fig. 1a left panel) and quantification of
features of plaque vulnerability, such as fibrous cap thickness,
plaque necrosis, and OS (Fig. 1a right top and bottom panels,
Supplementary Fig. 1a) was carried out17,18. Fibrous caps and
necrosis were assessed by histology, and OS was quantified by
mean fluorescence intensity after staining with dihydroethidium
(DHE), a fluorescent probe that detects superoxide in tissues.
Fibrous caps were significantly thicker in the regions that were
assigned to the stable group versus vulnerable group (Fig. 1a, top
right). Necrosis and DHE were higher in the regions that were
assigned to the vulnerable group versus stable group (Fig. 1a
bottom right panel and Supplementary Fig. 1a). Patient
characteristics are shown in Supplementary Table 1.
The vulnerable and stable regions were subjected to liquid
chromatography-tandem mass spectrometry (LC–MS/MS) for
targeted lipid mediator analysis. The major SPMs detected were
those that require 5-LOX for biosynthesis, namely, LXA4 and
RvD1, as depicted in the DHA and AA metabolomes in Fig. 1b,c.
The values are represented as pg of lipid mediators per gram of
tissue; the average weights of the specimens are shown in
Supplementary Table 2. Whereas the resolvin and maresin
biosynthetic intermediates 17- and 14-HDHA were significantly
higher in vulnerable compared with stable regions, RvD1 was
markedly decreased in the vulnerable regions. Interestingly, there
was a significant correlation between RvD1 and DHE levels
(Supplementary Fig. 1b), in which increased plaque reactive
oxygen species (ROS) correlated with decreased RvD1 levels. In
terms of AA-derived products, vulnerable regions contained
higher levels of 6-trans LTB4 (Po0.05, t-test), the non-enzymatic
hydrolysis product of LTA4, and there was a trend for lower levels
of LXA4 (Fig. 1c). When the two regions were compared for total
5-LOX-derived SPMs and for the ratio of these SPMs to LTB4,
vulnerable regions showed a striking decrease in both parameters
(Fig. 1d). To further interrogate these findings, we compared
vulnerable and stable regions from clinically defined symptomatic
or asymptomatic plaques for the above parameters. Total 5-LOX-
derived SPMs and the ratio of these SPMs to LTB4 was lower in
the vulnerable regions compared with stable areas of the
symptomatic plaques (Supplementary Fig. 1c), whereas these
relationships between lipid mediators and plaque region were
not statistically significant in the asymptomatic plaques
(Supplementary Fig. 1d). The full MS/MS spectra of RvD1,
LXA4, LTB4 and LXB4 identified in lesions are shown in
Supplementary Fig. 2a. This biochemical signature of inflamma-
tion-resolution imbalance has previously been linked to other
human inflammatory diseases8–10. We also identified other SPMs
in lesions, including protectin D1 (PD1), 17R-RvD3 and LXB4;
the levels of these SPMs, as well as the COX products
prostaglandins E2 and D2, were not different in vulnerable
versus stable plaques (Supplementary Fig. 2b,c; Tables 1 and 2).
RvE1 and maresin 1 (MaR1) were not detected in these samples
(Tables 1 and 2). In contrast, 5-HEPE and 15-HEPE, which are
5-LOX and 15-LOX monohydroxy products of EPA, respectively,
were increased in vulnerable regions, with a trend in that
direction for COX-2-derived 18-HEPE (Supplementary Fig. 2d),
suggesting that 5-LOX, 15-LOX and COX-2 are active in
vulnerable plaques. Thus, 5-LOX-derived SPMs are much lower
in vulnerable versus stable regions of human atherosclerotic
plaques despite the fact that the cells in the vulnerable regions are
still bioactive.
7-KC-induced OS suppresses RvD1 production. Because
vulnerable plaque regions had significantly more OS and
significantly less RvD1, we next asked whether OS could impair
RvD1 production as a possible mechanism of the decrease in
SPMs in vulnerable plaques. We incubated human macrophages
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Figure 1 | Human vulnerable atherosclerotic plaques have decreased 5-LOX SPM levels and a lower SPM:LT ratio than stable lesions. (a) Flash-frozen
human plaques were separated into vulnerable (V) and stable (S) regions (left panel), which were quantified for fibrous cap thickness:lesion area ratio (top
right panel) and percent plaque necrosis (bottom right panel). (t-test, **Po0.01, n¼ 8 donors). (b) Quantification of key DHA-derived lipid mediators, with
their respective biosynthetic pathways indicated (LOX, lipoxygenase). (c) Quantification of key AA-derived lipid mediators. (d) Comparison of 5-LOX-
derived SPMs (RvD1 and LXA4) and the SPM:LT ratio in vulnerable versus stable regions. For (b–d), t-test, *Po0.05, n¼ 15 donors. (e) Quantification of
RvD1 by ELISA in human macrophages that were incubated for 5 h with vehicle control, or 35 mM of 7KC, followed by Veh or 10mM DHA, for an additional
40min, and then the media were assayed for RvD1 with or without a 1 h pre-incubation with 10mM NAC. Data are shown as mean±s.e.m. (n¼4 separate
donors). Statistical analysis was conducted using one-way ANOVA with the Kruskal–Wallis test and Dunn’s multiple comparison post-hoc analysis,
*Po0.05 of n¼4 separate donors. (f) Quantification nuclear:non-nuclear 5-LOX ratio by confocal microscopy in macrophages incubated as in e, with two
additional groups, NAC alone and 7KCþNAC. Images were acquired on a Leica confocal microscope, and nuclear:non-nuclear 5-LOX MFI was quantified
using Image J. Data are shown as mean±s.e.m. (n¼4 separate donors). Statistical analysis was conducted using one-way ANOVA with the Kruskal–Wallis
test with the Dunn’s multiple comparison post-hoc analysis, *Po0.05.
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with a known inducer of OS found in human plaques,
7-ketocholesterol (7KC)19,20, and confirmed that 7KC stimulated
OS in a manner that was suppressed by the anti-oxidant
N-acetylcysteine (NAC) (Supplementary Fig. 3a). Under the
conditions of this experiment, 7KC did not induce apoptosis in
the macrophages, as indicated by no increase in cleaved caspase-
3, which is a measure of caspase-3 activation (Supplementary
Fig. 3b). Using this model, we found that DHA-stimulated RvD1
production by human macrophages was suppressed by 7KC and
that this suppression was abrogated by co-treatment with NAC
(Fig. 1e). As one possible mechanism for this effect, we
considered that 7KC may increase the ratio of nuclear:non-
nuclear 5-LOX, which would decrease the production of RvD1
(ref. 16). Indeed, 7KC increased this ratio in a manner that was
abrogated by NAC (Fig. 1f).
To further probe mechanism, we considered our previous
finding that CaMKII promotes nuclear 5-LOX by activating
MAPKAPK2 (MK2)-mediated phosphorylation of Ser 271 on
5-LOX16. In view of the data presented in the previous paragraph,
we were particularly interested in the finding by Anderson and
colleagues21,22 that, under OS conditions, oxidation of paired
methionine residues in the regulatory domain of CaMKII
(oxCaMKII) sustains the enzyme’s kinase activity in the
absence of Ca2þ /calmodulin. In this regard, we found that
7KC increases oxCaMKII in human macrophages, and this
increase was abrogated by RvD1 (Supplementary Fig. 3c). We also
found that 7KC led to the phosphorylation of both MK2 and
5-LOX-Ser271 and that RvD1 significantly reduced both of these
endpoints (Supplementary Fig. 3d,e). To prove causation, we
showed that silencing of CaMKII in human macrophages
suppressed the ability of 7KC to stimulate 5-LOX nuclear
localization (Supplementary Fig. 3f,g). In addition, the ability of
RvD1 to decrease 7KC nuclear localization was not enhanced in
CaMKII-silenced cells, suggesting that RvD1 exerts its action in a
CaMKII-dependent manner. Lastly, we found that CaMKII
silencing prevented the 7KC-mediated decrease of conversion of
DHA to RvD1 (Supplementary Fig. 3h). Note that 7KC
stimulation did not upregulate eicosanoid oxidoreductase, an
enzyme known to metabolize RvD1, which is consistent with
concept that the decrease in RvD1 by 7KC is primarily due to a
production defect rather than enzymatic inactivation
(Supplementary Fig. 4a). In summary, one mechanism of
decreased SPMs in advanced lesions could be decreased SPM
synthesis by macrophages via ROS-mediated activation of the
CaMKII-nuclear 5-LOX pathway.
Atheroprogression is associated with a decrease in lesional RvD1.
To determine whether the findings with human plaques might be
amenable to further experimentation in an animal model, we
conducted targeted LC–MS/MS analysis of aortic arch and
brachiocephalic artery (BCA) lesions of Ldlr / mice fed a
Western-type diet (WD) for 8 weeks (early lesions) or 17 weeks
(advanced lesions). Similar to human vulnerable plaques,
advanced murine plaques had significantly larger necrotic areas
and more lesional OS compared with early lesions (Fig. 2a). We
identified SPMs (RvD1, 17R-RvD1, 15R-LXA4 and PD1),
SPM biosynthetic pathway markers (for example, 17-HDHA,
18-HEPE, 4-HDHA), and several pro-inflammatory lipid
mediators, including LTB4 and prostaglandins (PGE2, PGD2 and
PGF2a) (Fig. 2b; Supplementary Table 3). Using Metaboanalyst
software (see ‘Methods’ section), we found that several of these
lipid mediators were significantly different in early versus
advanced lesions (Fig. 2b). Among these changes, RvD1 emerged
as being the most highly significantly changed mediator. To gain
an appreciation for the magnitude and direction of these changes,
we plotted the data as shown in Fig. 2c; red dots indicate those
mediators above the twofold threshold that were significantly
increased in advanced lesions, whereas red dots below the
threshold were considered significantly decreased mediators in
advanced lesions. The blue dots indicate mediators that were
Table 1 | Quantification of DHA-derived lipid mediators in
stable and vulnerable regions of human carotid
atherosclerotic plaques.
Lipid mediator Stable (pg g 1
(mean±s.e.m.))






















DHA, docosahexaenoic acid; ND, not detected.
*Po0.05 (paired analysis).
Table 2 | Quantification of AA- and eicosapentaenoic acid-
derived lipid mediators in stable and vulnerable regions of
human carotid atherosclerotic plaques.
Lipid mediator Stable (pg g 1
(mean±s.e.m.))























AA, arachidonic acid; ND, not detected.
*Po0.05 (paired analysis).
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either significantly changed or changed by more than twofold,
whereas the mediators indicated by black dots did not meet either
criterion. The data show a striking B87-fold significant decrease
in RvD1 in advanced versus early lesions. Other SPMs, such as
17R-RvD1, PD1 and LXB4, were also decreased in advanced
lesions, although to a lesser extent than RvD1. In contrast, early
and advanced lesions had similar amounts of LTB4 (Fig. 2c).
Importantly, the levels of 15-PGDH were not different between
Veh or RvD1-administered mice (Supplementary Fig. 4b),
suggesting that the decrease of RvD1 in advanced plaques may be
due to a production defect. Together, these data indicate that
the progression of atherosclerosis in WD-fed Ldlr / mice is
associated with a marked decrease in RvD1, while pro-inflam-
matory LTB4 levels are maintained. These findings are quantita-
tively similar to those found in the comparison of vulnerable
versus stable regions of human plaques.
Administration of RvD1 suppresses plaque progression.
Because RvD1:LTB4 ratio was reduced in advanced plaques, we
next questioned whether we could ‘restore’ this ratio to the early
lesional level by RvD1 administration to the mice and, if so,
suppress advanced plaque progression. For these experiments,
Ldlr / mice were fed the WD for either 8 weeks (early lesions)
or 17 weeks (advanced lesions), with vehicle control or 100 ng
RvD1/mouse (3 /wk i.p.) administered during the last 5 weeks
of the advanced lesion cohorts. As expected, RvD1 administration
increased lesional RvD1 levels (Fig. 3a, left panel). Importantly,
the absolute level of RvD1 (40.6±12.2 pg g 1) was not supra-
physiologic, as the level in early lesions was 152.9±23.6 pg g 1.
Moreover, LTB4 levels in lesions were significantly decreased by
RvD1 administration (Fig. 3a, middle panel), which is consistent
with our previous finding that RvD1 lowers LTB4 in macrophages
by increasing the ratio of non-nuclear:nuclear 5-LOX16. The
overall net effect was that RvD1 treatment restored the advanced
lesional ratio of RvD1:LTB4 to that of early lesions (Fig. 3a right
panel). Moreover, other SPMs and pathway markers of SPM
biosynthesis, including PD1, 17-HDHA, 15-HETE and MaR1
(ref. 23) were increased by RvD1 (Supplementary Fig. 5a;
Supplementary Table 3). In contrast, the COX products PGE2,
PGD2 and PGF2a were not affected by RvD1 treatment
(Supplementary Fig. 5b; Supplementary Table 3). Monohydroxy
products of 5-LOX, including 5-HETE, 5-HEPE, 4-HDHA and
7-HDHA, were also detected and quantified (Supplementary
Fig. 5c; Supplementary Table 3). The increase of 4-HDHA and
the lack of suppression of the other monohydroxy 5-LOX
products suggest that RvD1 does not act as a 5-LOX inhibitor. In
summary, restoring RvD1 during the time period when earlier
lesions are progressing to advanced lesions reestablishes the
balance of SPM to pro-inflammatory leukotrienes.
On the basis of our previous data linking oxidative activation of
CaMKII to an increase in nuclear 5-LOX and a decrease in the
SPM:leukotriene ratio in cultured macrophages, we probed
oxCaMKII in the early versus advanced murine lesions, including
advanced lesions from mice subjected to RvD1 restoration. We
observed that advanced lesions had significantly more immunor-
eactive oxCaMKII compared with early lesions and that RvD1
restoration significantly decreased lesional oxCaMKII in these
lesions (Fig. 3b). Moreover, using confocal immunofluorescence
microscopy, we observed that RvD1 restoration decreased the
nuclear:non-nuclear 5-LOX ratio in advanced lesional macro-
phages (Fig. 3c; Supplementary Fig. 6). These combined data
provide correlative in vivo support for the hypothesis that
oxidative activation of CaMKII in advanced lesional macrophages
contributes to an imbalance of 5-LOX-derived resolving versus
inflammatory lipid mediators in a manner that can be prevented
by RvD1 restoration.
Having achieved the goal of restoring RvD1:leukotriene
balance in advanced lesions, we then analyzed the mice for basic
metabolic parameters and, most importantly, for hallmarks of
advanced plaque progression that are associated with vulnerable
plaques in humans11. RvD1 had no effect on body weight, plasma
cholesterol, plasma insulin or plasma MCP-1 levels (Supple-
mentary Fig. 7a–d). As expected, aortic root plaques of the
vehicle-treated mice exhibited robust DHE and NOX2 staining,
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Figure 2 | Advanced aortic root plaques of WD-fed Ldlr/ mice exhibit
an imbalance in 5-LOX-derived SPMs and LTs compared with earlier
stage lesions. (a) Aortic root lesions from Ldlr/ mice fed the WD for 8
weeks (Early) or 17 weeks (Advanced) were quantified for necrotic area and
mean fluorescence intensity after DHE staining (data are shown as
mean±s.e.m., t-test, ***Po0.001, n¼ 7 for early lesions and n¼ 11 for
advanced plaques). (b,c) Analysis of lipid mediators in advanced versus
early atherosclerotic plaques. Red dots indicate mediators that both
reached statistical difference by Student’s t-test ( log10 of the P-value)
and changed by at least twofold (log2); blue dots indicate mediators that
met only one of these criteria; and black dots represent lipid mediators that
met neither of these criteria. For b and c, n¼8 for early lesions and n¼ 11
for advanced lesions.
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necrotic cores (Fig. 4b, left image and white bar of graph). We
found that RvD1 markedly reduced both of these endpoints
(Fig. 4a,b, grey bars of graph). Defective clearance of apoptotic
cells (efferocytosis) in advanced plaques promotes plaque
necrosis2,12, and, in other settings, RvD1 has been shown to
enhance efferocytosis24. By quantifying macrophage-associated
apoptotic cells versus free apoptotic cells in lesions as a measure
of efferocytosis25, we found that RvD1 significantly enhanced
lesional efferocytosis (Fig. 4c; Supplementary Fig. 8a) without
affecting lesional apoptosis (Supplementary Fig. 8b). Another
hallmark of advanced plaques is thinning of the ‘protective’
fibrous collagenous cap that overlies necrotic areas2,11. While the
aortic root lesions of the vehicle-treated control group had
relatively thin fibrous caps, those in the RvD1 group had
significantly thicker fibrous caps (Fig. 5a). Note that RvD1 did not
























































































































Figure 3 | Administration of RvD1 to WD-fed Ldlr/ mice with established atherosclerosis restores lipid medicator balance. (a) Quantification of
lesional RvD1 and LTB4 levels (left and middle panels) and RvD1:LTB4 ratio (right panel) in aortic lesions of 17-week WD-fed Ldlr
/ mice that were
administered vehicle control (Veh) or 100 ng RvD1/mouse (3 /week i.p.) during weeks 12–17; the ratio data in 3a right panel are also shown for mice fed
the WD for 8 weeks (Early lesions). For a, data are shown as mean±s.e.m., one-way ANOVA with Fisher’s least significant difference post-hoc analysis,
*Po0.05, n¼ 8 for early lesions, n¼ 11 for advanced lesions/Veh group, and n¼ 10 for advanced lesions/RvD1 group. (b) Representative images and
quantification of lesional oxCaMKII by immunofluorescence microscopic analysis. MFI data are shown as mean±s.e.m., one-way ANOVA with Tukey’s
multiple comparison test, *Po0.05 and ***Po0.001 early lesions versus other groups. ^Po0.05 Veh versus RvD1 groups, n¼ 8 for early lesions, n¼ 11 for
advanced lesions/Veh group, and n¼ 10 for advanced lesions/RvD1 group. Scale bar, 100 mm. (c) Representative confocal immunofluorescence images and
quantification of 5-LOX localization in aortic lesional macrophages of 17-week WD-fed Ldlr/ mice given vehicle control (Veh) or RvD1 during weeks
12–17. Macrophage F4/80 is red, 5-LOX is green, and Hoechst (nuclei) is blue. Arrows indicate nuclear region. In these images, nuclear 5-LOX appears as
blotchy light blue staining within the dark blue Hoechst-stained nuclei. The quantitative data are shown as mean±s.e.m., t-test, *Po0.05, n¼ 11 for Veh
group and n¼ 10 for RvD1 group. Scale bar, 5 mm.
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(Supplementary Fig. 7e,f), indicating that its protective effects
were not being mediated by regulating the number of these cells
in lesions. In this regard, advanced plaques exhibited robust
staining of both collagenase and MMP9 (Fig. 5b,c), while RvD1
significantly reduced both endpoints (Fig. 5b,c). Together, these
results indicate that RvD1 restores the RvD1:LTB4 balance in
advanced plaques and, in association with this effect, suppresses

























































































Figure 4 | Administration of RvD1 to mice with established atherosclerosis suppresses lesional ROS and necrosis and enhances efferocytosis. (a)
Representative images of DHE and quantification of immunoreactive NOX2 and DHE in aortic root lesions of 8-week and 17-week WD-fed Ldlr/ mice
given vehicle control (Veh) or RvD1 for weeks 12–17 (Fig. 3). Scale bar, 100 mm. Data are shown as mean±s.e.m., one-way ANOVA with Tukey’s multiple
comparison test, ***Po0.001 early lesions versus other groups. ^^Po0.01 Veh versus RvD1 groups, n¼8 for early lesions, n¼ 11 for advanced lesions,
n¼ 10 for advanced lesions/RvD1 group. (b) Representative images and quantification of lesional necrosis in the two cohorts of mice. Scale bar, 100mm.
(c) Representative images and quantification of lesional efferocytosis, quantified as the ratio of TUNELþ apoptotic cells (red) associated with lesional
macrophages (green) versus apoptotic cells not associated with macrophages (‘free’). Yellow indicates red/green overlap, and blue indicates DAPI-stained
nuclei. Scale bar, 5 mm. Data are shown as mean±s.e.m., t-test, *Po0.05, **Po0.01, n¼ 11 for Veh group and n¼ 10 for RvD1 group.
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Discussion
The findings of this study provide critical molecular support to
the concept that defective resolution of inflammation contributes
to atherosclerosis progression1,2,13,26, and they offer a new
framework to understand how this defect may develop.
Moreover, the finding that advanced plaque progression can be
suppressed by ‘normalizing’ resolution:inflammation imbalance
during a critical period of plaque transformation adds causative
support for the concept and provides a mechanistic underpinning
to recent studies showing the benefits of resolving mediator
therapy in atherosclerosis27–30.
More than two decades ago, Serhan and colleagues31 found
that angioplasty increased the levels of certain leukotrienes and
lipoxins in human coronary arterial blood, suggesting that
coronary arterial cells could carry out lipid mediator
biosynthesis. Following that discovery, correlations were
reported for high levels of plasma leukotrienes and plaque
instability in humans32. In this regard, the LTB4 receptor BLT1 is
expressed by human lesional cells and triggers inflammatory
signalling pathways33. Leukotrienes promote chemotaxis of
inflammatory cells and enhance the production of other
pro-inflammatory mediators that, when in excess, can
exacerbate vascular disease34. There have also been reports that
atherosclerotic disease in humans is correlated with low levels
of SPMs in the plasma, including aspirin-triggered LXA4
(refs 35,36).
The situation is more complex with 5-LOX, which can give rise
to either inflammatory or resolving mediators, and 12/15-LOX,
which can promote either SPM synthesis or pro-atherogenic
oxidation of LDL1,26,37–39. A possible determinant as to whether
these pathways promote or suppress plaque progression may be
the relative types of long-chain fatty acids in the diet, because
essential omega-6 fatty acids (for example, AA) can promote the
local synthesis of pro-inflammatory mediators, while omega-3
fatty acids can promote the local biosynthesis of pro-resolving
mediators5. In Apoe / mice, a high omega-3:omega-6 ratio was
found to be associated with decreased atherosclerosis40, although
whether this effect was caused by alterations in lipid mediators is
not known. In humans, individuals with a specific ALOX5 variant
who also ingested a diet rich in AA had increased carotid
atherosclerosis compared with individuals with non-variant
ALOX5, while those with the same mutation but who ingested
a diet rich in omega-3 fatty acids had less carotid atherosclerosis
compared with the control population41. More recent work
indicated a trend between EPA and a 5-LOX variant in lowering
CVD risk (P¼ 0.06)36. Further studies need to be carried out to
determine the functions of these SNPs and to reconcile the results
of a few clinical trials that failed to show a protective effect of
dietary fish oils42. Other possible determinants of the balance of
5-LOX products include factors that affect the nuclear versus
non-nuclear location of 5-LOX, such as oxysterols/OS as
demonstrated here, and SPMs themselves, as recently published
by us16. Other processes that can affect SPM production and that
could, in theory, play roles in atherosclerosis include cell-cell
communication and transcellular biosynthesis5; release of LX
precursors from cellular phospholipids43; and action of 5-LOX
activating protein (FLAP), which may play a role in LX
production44–47. Leukotriene A4 hydrolase (LTA4H) is also
emerging as an intriguing target for atherosclerosis, because
inhibition of this enzyme has been linked to the decrease of
leukotriene B4 and the increase of lipoxins32,44,48.
One of the most striking features of RvD1 administration was
its ability to increase the fibrous cap. In support of these findings,
RvE1 increased collagen in the context of periodontal ligament
repair49 and 17R-RvD1 was shown to increase matrix synthesis in
a model of arthritis50. On the other hand, RvD1 was found to
decrease cardiac collagen in the setting of myocardial infarction51,
and there are several reports that suggest SPMs exert anti-fibrotic
actions52,53. Thus, the role of SPMs in fibrosis appears to be
context-specific, and factors that control its actions in collagen
synthesis versus degradation in advanced atherosclerosis
represents an important area for future investigation.
Exogenously administered SPMs have shown benefit in other
vascular settings, including injury-induced neointimal hyperpla-
sia and monocyte recruitment during early atherogenesis28,54.
However, these settings are very different from the one examined
in this report—advanced atherosclerosis. Furthermore,
mechanistic links represent a major gap in this area of research.
Given the importance of defective efferocytosis in necrotic core
formation and advanced plaque progression2, one key link likely
involves the beneficial effect of SPMs on efferocytosis5,55,
including that shown here for RvD1. Advanced plaques
also have elevated OS18. In this context, we showed that
7-KC-induced OS in human macrophages lowered RvD1 levels
and that DHE fluorescence in human lesions, which is an
indicator of OS, showed a negative correlation with lesional
RvD1. Pending more in-depth analysis of various ROS in the
atherosclerotic lesions investigated in this study, our combined
in vitro and in vivo data thus far suggest that OS may be one
mechanism leading to lower RvD1 levels in advanced lesions. It is
also possible that a deficiency in RvD1 exacerbates OS in






























































Figure 5 | Administration of RvD1 to WD-fed Ldlr/ mice with
established atherosclerosis enhances fibrous caps and decreases
collagenase and MMP9. (a) Representative images and quantification of
collagen of 17-week WD-fed Ldlr/ mice given vehicle control (Veh) or
RvD1 for weeks 12–17 (Fig. 3). Scale bar, 100mm. (b,c) Representative
images and quantification of collagenase and MMP9. Scale bar, 100mm.
Data are shown as mean±s.e.m., t-test, **Po0.01 and ***Po0.001, n¼ 11
for Veh group and n¼ 10 for RvD1 group.
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defective efferocytosis56. In terms of therapeutic implications of
these concepts, we showed recently that treatment of WD-fed
Ldlr / mice with plaque-targeted nanoparticles containing
Ac2–26, a bioactive peptide derived from the pro-resolving
protein called annexin A1, exhibited increased fibrous cap
thickness and decreased OS and necrosis compared with
control mice27. Ac2–26 and RvD1, the mediator used here,
activate the same G-protein-coupled receptor called ALX/FPR2
(refs 24,57). Thus, stimulating pro-resolving signalling via
ALX/FPR2 may be a promising therapeutic strategy to prevent
vulnerable plaque formation.
In summary, we have shown that the levels of 5-LOX-derived
SPMs, particularly RvD1, are lower in human vulnerable versus
stable plaques and murine advanced versus early lesions and that
restoration of the RvD1:LTB4 ratio in murine plaques protects
against advanced plaque progression. These findings add a critical
new molecular link to the concept that resolution of inflamma-
tion is defective in advanced atherosclerosis and provide
a rationale for developing ‘SPM-restoration’ therapy to help
prevent the clinical progression of atherosclerosis in humans.
Methods
Human carotid endarterectomy analysis. De-identified atherosclerotic plaques
from elective endarterectomy procedures were obtained with informed consent and
then immediately snap frozen in the operating room using liquid nitrogen.
Specimens were then dissected into ‘vulnerable’ and ‘stable’ regions based on gross
appearance. Gross necrotic regions were identified by dark brown regions and
were dissected from less necrotic regions of the same donor. For human plaque
histology, vulnerable and stable plaques from each donor were fixed using 10%
formalin overnight at room temperature (RT). Tissue was then washed with PBS
and decalcified using calcic-clear rapid solution (National Diagnostics) for 3 h at
RT. Human plaques were placed in biopsy cassettes, processed in a Leica tissue-
processing machine, and embedded in paraffin blocks. Sections were cut serially at
8-mm intervals and mounted on slides. Before staining, sections were deparaffinized
in xylene and rehydrated in graded series of ethanol. For plaque necrosis mea-
surements, the sections were stained with Harris’ hematoxylin and eosin (H&E).
Total lesional and necrotic areas were quantified using Image Pro Plus software.
Lesional collagen was stained with picrosirius red as per the manufacturer’s
instructions (PolySciences), and the ratio of fibrous cap thickness to total lesion
area was quantified with image processing software27,58,59. Dihydroethidium
bromide (DHE, Life Technologies) was used per manufacturer’s instructions,
and total plaque mean fluorescence intensity (MFI) was quantified using ImageJ
software. Vulnerable and stable lesions from each donor were then subjected to
tandem mass spectrometry for lipid mediator analysis (see below for more details).
Lipid mediators were calculated as picogram per gram of frozen tissue. The
Columbia University IRB provided ethical approval for these studies and
procedures were conducted in accordance with an approved IRB protocol.
Human macrophage experiments. Buffy coats were purchased from the New
York Blood Donor Center, and peripheral blood mononuclear cells (PBMCs) were
isolated using Histopaque 1077 (Sigma). Briefly, buffy coat cells were carefully
loaded onto Histopaque 1077 and then spun at 1,500 r.p.m. for 30min at room
temperature. The centrifuge was set to ‘no brake’ to preserve the separation of the
cells. PBMCs were collected and washed twice with PBS. Sixty million PBMCs were
plated on a 10-cm petri dish for 30min to allow for monocyte adhesion. After
30min, non-adherent cells were removed by rinsing with PBS, and the attached
cells were cultured with RMPI-1640 containing 10% FBS and 10 ngml 1 of
recombinant human GM-CSF for 7 days60. (Fresh GM-CSF-containing media
was supplemented on day 3). In some experiments, the macrophages (3 106
cells/treatment) were incubated with 35 mM of 7KC or vehicle control for 5 h. The
macrophages were then analyzed for ROS using a CellROX probe (Invitrogen)
or fixed, permeabilized and stained with an antibody against cleaved caspase-3
(Cell Signaling). CellROX-stained images were acquired using a Bio-Rad Zoe
fluorescence microscope, and images were analyzed using ImageJ software. Cleaved
caspase-3 was quantified by flow cytometry using FlowJo software. In other
experiments, the cells were sequentially incubated with 10 mM NAC for 1 h and
then 35mM of 7KC or vehicle for 5 h, after which either 10 mM DHA or vehicle was
added for an additional 1 h. The media were then collected and assayed for RvD1
by ELISA (Cayman Chemicals).
Macrophage 5-LOX localization. The ratio of nuclear to non-nuclear 5-LOX
mean florescence intensity (MFI) was quantified by confocal immunofluorescence
microscopy, as previously described16. Briefly, macrophages (60,000 cells per well
in an 8-well coverslip) were fixed with 4% formalin for 15min. After removal of the
formalin, the cells were incubated with 1:100 anti-5-LOX antibody (Abcam
#ab39347) in 1 PermWash buffer (BD Biosciences) for 45min and then with
1:200 goat-anti-rabbit IgG secondary antibody conjugated to Alexa 488 for 45min.
After counterstaining with Hoechst, the cells were imaged on a Leica confocal
microscope. An average of 15–20 cells per treatment per donor were analyzed.
Immunoprecipitation. Human macrophages were incubated for 3 h with 35 mM
7KC, 10 nM RvD1, 7KCþRvD1, or vehicle. For immunoprecipitation (i.p.)
experiments, incubations were stopped using liquid nitrogen, and the cells
were immediately collected in i.p. buffer. SureBeads (Bio-rad, #1614013) were
conjugated to anti-CaMKII antibody (kind gift of Dr Harold Singer, Albany
Medical College) or control IgG according to the manufacturer’s instructions.
The beads (100 ml) were added to 300 ml cell lysate, and the mixture was incubated
overnight at 4 C. The immunoprecipitates were collected by centrifugation
and subjected to 10% SDS gel electrophoresis. Membranes were probed with anti-
oxCaMKII at a 1:1,000 dilution (kind gift from Dr Mark E. Anderson, University of
Iowa22,61), followed by an anti-rabbit light chain IgG (Abcam, #ab99697, 1:4,000).
siRNA experiments. Human macrophages were incubated for 72 h with 1 mM of
Accell human Camk2g siRNA SMARTpool (Dharmacon) or control siRNA
(Dharmacon) in RPMI 1640 media containing 1% FBS. To confirm knockdown,
cells were subjected to flow cytometry (below). The cells were then incubated for
5 h with 35 mM 7KC, 10 nM RvD1, 7KCþRvD1 (added at the same time), or
vehicle control. 5-LOX localization and RvD1 ELISA were carried out as above.
Flow cytometry. For signalling experiments, formalin-fixed human macrophages
(above) were incubated with either anti-pMK2 (Cell Signaling, 3007) or anti-p-5-
LOX-Ser271 (Cell Signaling, 3748) in 1 permeabilization buffer (BD Biosciences)
for 45min on ice. For siRNA knockdown confirmation, macrophages (above) were
fixed, then incubated with the CaMKIIg antibody from Genetex in 1 permea-
bilization buffer for 1 h on ice. Excess antibody was removed, and the cells were
then incubated with goat-anti-rabbit IgG secondary antibody conjugated to Alexa
488 or Alexa 647 in 1 permeabilization buffer for an additional 45min on ice.
Flow cytometric analysis was carried out using a FACsCaliber flow cytometer and
FlowJo software.
Murine atherosclerotic lesion analysis. Eight to ten week-old male Ldlr /
mice on the C57BL/6J background were purchased from Jackson Laboratory (stock
# 002207) and placed on a WD (TD.88137, Harlan Talked) for 8–17 weeks. After
12 weeks on the WD, some of the cohorts were injected i.p. three times per week
with 500 ml of sterile PBS (vehicle control) or RvD1 (100 ng/mouse) for an addi-
tional 5 weeks, while still on the WD. The Columbia University IACUC provided
ethical approval for these studies and procedures were conducted in accordance
with approved animal protocols. Necrotic core analysis was carried out on
H&E-stained lesional cross sections as previously described62. Briefly, using light
microscopy and image analysis software, boundary lines were drawn around areas
lacking hematoxylin stained nuclei (acellular), and these areas were then quantified
using a 10,000 mm2 threshold to avoid including regions that did not represent
substantial areas of necrosis. Collagen staining was performed using picrosirius red
as per the manufacturer’s instructions (PolySciences) and analyzed as previously
described27. All experiments were carried out in two separate cohorts each with
B5 mice/group/cohort.
Quantification of lipid mediators by metabololipidomics. Human endarter-
ectomy or mouse atherosclerotic lesion samples were immediately snap frozen and
stored at  80 C. As described previously63, frozen samples were weighed,
combined with 1ml of ice-cold methanol containing deuterium-labeled internal
standards (d5-RvD2, d4-LTB4, d8-5-HETE, d4-PGE2 and d5-LXA4), homogenized,
and kept at  20 C for 45min to allow protein precipitation. Samples were
centrifuged and supernatants were collected. Solid phase extraction was carried out
on an automated extraction system (RapidTrace, Biotage) using C18 extraction
cartridges. Following column conditioning with 3ml of methanol followed by 6ml
of H2O, acidified samples (pH¼ 3.5, HCl) were loaded onto the columns. Columns
were washed with 4ml of H2O followed by 5ml of hexane, and lipid mediators
were eluted with 9ml of methyl formate. A steady stream of N2 gas was used to
slowly concentrate the samples before complete re-suspension in methanol:water
(50:50). Samples were injected and analyzed by LC–MS/MS using a high
performance liquid chromatography system (HPLC; Shimadzu) coupled to a
QTrap 6500 or QTrap5500 mass spectrometer (AB Sciex) operating in negative
ionization mode using scheduled multiple reaction monitoring (MRM),
information-dependent acquisition and enhanced product ion-scanning. A
Poroshell column (100mm 4.6mm 2.7 mm, Agilent) was kept in a column
oven maintained at 50 C (ThermaSphere), and lipid mediators were eluted with a
mobile phase consisting of methanol–water–acetic acid of 50:50:0.01 (vol/vol/vol)
isocratic for 2min that was ramped to 80:20:0.01 (vol/vol/vol) over 9min, kept
isocratic for 3.5min, and then ramped to 98:2:0.01 (vol/vol/vol) for the next
0.1min, which was maintained for 5.4min at 0.5mlmin 1. Lipid mediators were
identified using published criteria including retention time, MRM transitions, and
diagnostic MS/MS ions and were quantified using standard curves for each
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mediator after normalization of extraction recovery based on internal deuterium-
labelled standards63. To analyze the differences between early and advanced
murine atherosclerotic lesions in an unbiased manner, we used Metaboanalyst 3.0
(http://www.metaboanalyst.ca). Missing values were imputed with half of the
minimum positive value, and data were log transformed and autoscaled before
analysis. Global changes between the groups were compared using Student’s t-tests
(Po0.05) and a fold-change threshold of 2.
Immunofluorescence staining of murine lesions. For assessment of collagenase
activity, aortic root lesions from Veh or RvD1-treated mice were analyzed using a
collagenase assay kit from ThermoFisher in accordance with the company’s
guidelines. Briefly, collagenase substrate (1:50) was incubated with lesion sections
overnight at 37 C. After rinsing with PBS, the sections were imaged by fluores-
cence microscopy and analyzed using ImageJ software. For immunofluorescence
microscopy, aortic root sections were fixed in ice-cold acetone for 5min, washed in
PBS, and blocked with DAKO protein block for 1 h at room temperature. Sections
were then incubated overnight at 4 C with antibodies against NOX2 (Abcam,
ab80508), 15-PGDH (Genetex, GTX113740), MMP9 (Abcam, ab38898), oxCaM-
KII (Millipore, 07–1387), or alpha smooth muscle cell actin (Sigma, C6198), F4/80
(Bio-Rad, MCA497) all at 1:100 in the DAKO protein block solution. The sections
were then rinsed, stained with a secondary antibody, rinsed again, viewed by
fluorescence microscopy, and analyzed using ImageJ software.
Murine aortic root confocal microscopy. Cross sections of murine aortic root
lesion were stained at 4 C with anti-5-LOX antibody and then anti-F4/80. The
sections were counterstained with Hoechst to identify nuclei, viewed on a Nikon
A1 confocal microscope, and analyzed using ImageJ software16.
In situ efferocytosis. The efferocytosis assay was performed on frozen aortic root
sections and was conducted using procedures previously described25. Briefly, an
observer who was blinded to the identity of the samples quantified apoptotic
(TUNEL-positive) nuclei (DAPI) that were associated with lesional macrophages,
indicative of efferocytosis, or not associated with macrophages (‘free’).
Macrophage-associated apoptotic cells followed the criteria of TUNEL-positive
nuclei surrounded by or in contact with neighbouring F4/80þ macrophages. Free
apoptotic cells exhibited nuclear condensation, loss of antibody F4/80 reactivity,
and were not in contact with neighbouring macrophages.
Statistical analysis. All mice were randomly selected to be in either the early or
advanced group, and, for the advanced group, to receive either vehicle or RvD1. No
mice were excluded from any of the groups. There were at least 10 mice per
experimental group, and all data were found to fit a normal distribution. Results are
shown as mean±s.e.m. For comparison between two experimental groups, the
two-tailed Student’s t-test was used, and for comparison among three experimental
groups, one-way ANOVA with Fisher’s least significant difference post-hoc analysis
was used. The human macrophage experiments used at least three separate human
donors per experiment, and so nZ3 for each experimental group. Results are
shown as mean±s.e.m, and statistical differences were determined using the
Kruskal–Wallis test with the Dunn’s multiple comparison post-hoc analysis.
Data availability. The data that support the findings of this study are available
from the corresponding author upon reasonable request.
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